Safety
GLP-1 medicines, pregnancy, and oral contraception
Pregnancy planning and contraception should be discussed before starting a GLP-1 medicine. The instructions differ by product and cannot be replaced by one class-wide rule.
Make a plan with the prescriber
Weight-management medicines are not a treatment for weight loss during pregnancy. The relevant labels advise actions when pregnancy occurs; discuss these before treatment and contact the prescriber promptly if pregnancy is suspected or recognized.
Semaglutide labels include discontinuation at least 2 months before a planned pregnancy because of its long washout period. The exact indication and clinical circumstances matter, so the clinician should coordinate diabetes or other care during a change in treatment. Do not stop all related medicines without a replacement care plan.
Sources: Wegovy prescribing information, including tablets and Wegovy HD · Ozempic prescribing information
Tirzepatide and oral hormonal contraception
Mounjaro and Zepbound delay gastric emptying and can reduce oral hormonal contraceptive effectiveness. Their labels advise switching to a non-oral method or adding a barrier method for 4 weeks after initiation and for 4 weeks after every escalation.
Moving the injection to another hour does not remove the precaution. Ask which contraceptive method and backup approach fit your circumstances, and discuss vomiting or diarrhea that may affect oral medicine use.
Sources: Mounjaro prescribing information · Zepbound prescribing information
Foundayo uses different wording
Foundayo's label advises a non-oral contraceptive method or added barrier protection for 30 days after starting and for 30 days after each dose escalation. This is a separate product-specific instruction, not a reason to use tirzepatide's exact 4-week rule for every pill.
Foundayo also has medicine interactions requiring review. Bring the full medication and contraception list to the prescriber or pharmacist rather than focusing only on the weight-management prescription.
Sources: Foundayo prescribing information
Breastfeeding and restarting
Breastfeeding guidance is formulation-specific. The current Wegovy label advises against breastfeeding during tablet treatment; other products need review of their own labeling and the individual's circumstances.
After pregnancy, breastfeeding, or a prolonged interruption, discuss whether restarting is appropriate and which dose should be used. The pre-interruption dose should not be resumed automatically. This page is for planning a clinical discussion, not choosing contraception or a pregnancy treatment plan.
Sources: Wegovy prescribing information, including tablets and Wegovy HD · Foundayo prescribing information · Mounjaro prescribing information · Zepbound prescribing information
Put pregnancy planning and escalation on the same calendar
A pregnancy plan should be discussed before treatment begins, including what to do if pregnancy is suspected. Semaglutide has a two-month planned-pregnancy discontinuation instruction because of its long washout, with attention to the product and indication. Wegovy applies that instruction to weight or cardiovascular-risk treatment, and to MASH when the potential risk outweighs benefit. For MASH, its label allows pregnancy use only when potential benefit justifies fetal risk; this requires specialist assessment. These instructions should not become a universal stop interval for every GLP-1-related medicine.
For weight-management treatment, contact the prescriber promptly when pregnancy is recognized and follow the product's instructions. If diabetes is also being treated, the clinician must plan appropriate glucose care rather than leave the condition unmanaged. Do not wait for a routine refill visit to disclose pregnancy plans or a possible pregnancy. Discuss the exact medicine, other treatment, contraception, and timing with the relevant clinicians so the plan is coherent across care teams.
Sources: Wegovy prescribing information, including tablets and Wegovy HD · Ozempic prescribing information · Mounjaro prescribing information · Foundayo prescribing information
Why the added-protection period can recur
For tirzepatide, oral hormonal contraception requires a non-oral method or added barrier protection for four weeks after starting and after each dose increase. Foundayo uses 30 days after initiation and each escalation. The periods sound similar but should be kept in the product's exact wording. Dose increases can create another protection period even after the initial treatment month has ended.
Ask the prescribing and contraception clinicians which approach is appropriate and how to record the dates. Taking the contraceptive pill at a different hour is not a replacement for the labeled precaution. Vomiting or diarrhea can introduce additional contraception questions that should be addressed with the contraceptive product's guidance and a clinician. Do not assume every GLP-1 has the same instruction or that an injection avoids all absorption concerns for oral medicines.
Sources: Mounjaro prescribing information · Zepbound prescribing information · Foundayo prescribing information
Revisit the plan for breastfeeding or a product switch
Breastfeeding advice also differs by product and formulation. The Wegovy label advises against breastfeeding during tablet treatment; a general statement that all semaglutide routes have identical advice would omit that distinction. Ask the clinician to review the actual label and the individual's treatment needs rather than extrapolating from another patient's experience.
If switching from semaglutide to tirzepatide, Foundayo, or another product, revisit pregnancy timing and contraception instead of retaining the old instructions by habit. The new prescription should identify start timing and any additional precautions. A compounded preparation does not provide a shortcut around these clinical questions or acquire the approved product's evidence automatically. Keep the medication list current and ensure clinicians managing diabetes, weight, and reproductive care know about the same plan.
Sources: Wegovy prescribing information, including tablets and Wegovy HD · Foundayo prescribing information · Zepbound prescribing information · FDA concerns with unapproved GLP-1 drugs used for weight loss
Sources and evidence
Sources checked October 2, 2026. Prescribing information supports medication facts; provider pages support advertised services. Offers and labels can change.